IS7189A - Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra - Google Patents

Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra

Info

Publication number: IS7189A
Authority: IS; Iceland
Prior art keywords: somatostatin; diagnosis; treatment; bombesin analogues; bombesin
Prior art date: 2001-09-21

Application number

IS7189A

Other languages

English (en)

Inventor

H. Coy David

A. Fuselier Joseph

A. Murphy William

Sun Lichun

Original Assignee

The Administrators Of The Tulane Educational Fund

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-21

Filing date

2004-03-19

Publication date

2004-03-19

2004-03-19 Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund

2004-03-19 Publication of IS7189A publication Critical patent/IS7189A/is

Links

102000005157 Somatostatin Human genes 0.000 title 1
108010056088 Somatostatin Proteins 0.000 title 1
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 title 1
238000003745 diagnosis Methods 0.000 title 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
229960000553 somatostatin Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Percussion Or Vibration Massage (AREA)

IS7189A 2001-09-21 2004-03-19 Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra IS7189A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32385101P	2001-09-21	2001-09-21
PCT/US2002/030143 WO2003028527A2 (en)	2001-09-21	2002-09-20	Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof

Publications (1)

Publication Number	Publication Date
IS7189A true IS7189A (is)	2004-03-19

Family

ID=23260992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7189A IS7189A (is)	2001-09-21	2004-03-19	Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra

Country Status (16)

Country	Link
US (1)	US7326685B2 (is)
EP (1)	EP1435826A4 (is)
JP (1)	JP4799820B2 (is)
KR (1)	KR20040047846A (is)
CN (1)	CN1589151A (is)
AU (1)	AU2002341792B2 (is)
BR (1)	BR0212897A (is)
CA (1)	CA2461099A1 (is)
IL (2)	IL160993A0 (is)
IS (1)	IS7189A (is)
MX (1)	MXPA04002621A (is)
NO (1)	NO20041186L (is)
NZ (1)	NZ532204A (is)
PL (1)	PL369336A1 (is)
WO (1)	WO2003028527A2 (is)
ZA (1)	ZA200402698B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6721705B2 (en) *	2000-02-04	2004-04-13	Webley Systems, Inc.	Robust voice browser system and voice activated device controller
NZ534719A (en)	2002-03-01	2008-02-29	Univ Tulane	Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US8060626B2 (en) *	2008-09-22	2011-11-15	Sony Computer Entertainment America Llc.	Method for host selection based on discovered NAT type
US7977049B2 (en) *	2002-08-09	2011-07-12	President And Fellows Of Harvard College	Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
KR100817232B1 (ko) *	2003-04-22	2008-03-27	소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스.	펩타이드 벡터
JP2007530417A (ja) *	2003-07-01	2007-11-01	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	細胞及び生物の寿命及びストレス応答を操作するための組成物
US20060025337A1 (en) *	2003-07-01	2006-02-02	President And Fellows Of Harvard College	Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US8017634B2 (en)	2003-12-29	2011-09-13	President And Fellows Of Harvard College	Compositions for treating obesity and insulin resistance disorders
CA2548671C (en)	2003-12-29	2015-02-24	President And Fellows Of Harvard College	Compositions for treating or preventing obesity and insulin resistance disorders
US20050255045A1 (en) *	2004-05-13	2005-11-17	Woltering Eugene A	Surgical marking composition and method
CA2467321A1 (en) *	2004-05-14	2005-11-14	Paul J. Santerre	Polymeric coupling agents and pharmaceutically-active polymers made therefrom
JP5247144B2 (ja) *	2004-05-14	2013-07-24	インターフェースバイオロジクスインコーポレーティッド	高分子カップリング剤およびそれらから製造された薬学的に活性のあるポリマー
AU2005262472B2 (en) *	2004-06-16	2011-10-27	President And Fellows Of Harvard College	Methods and compositions for modulating bax-mediated apoptosis
US20060014705A1 (en) *	2004-06-30	2006-01-19	Howitz Konrad T	Compositions and methods for selectively activating human sirtuins
WO2006138418A2 (en) *	2005-06-14	2006-12-28	President And Fellows Of Harvard College	Improvement of cognitive performance with sirtuin activators
NZ562109A (en) *	2005-06-16	2011-03-31	Myrexis Inc	Pharmaceutical compositions containing substituted (4-Phenyl)-methyl-(quinazolin-4-yl)-amine compounds, uses thereof, and methods of preparing the same
WO2007097318A1 (ja) *	2006-02-23	2007-08-30	Adeka Corporation	診断用マーカー
DE102006035083A1 (de) *	2006-07-28	2008-01-31	medac Gesellschaft für klinische Spezialgeräte mbH	Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
US8691761B2 (en)	2006-10-16	2014-04-08	Jean E. F. Rivier	Somatostatin receptor 2 antagonists
EP2433963B1 (en)	2006-10-16	2014-06-04	The Salk Institute for Biological Studies	Receptor (SSTR2)-selective somatostatin antagonists
RU2457218C2 (ru)	2006-10-20	2012-07-27	Ипсен Фарма С.А.С.	Конъюгаты цитотоксических средств с пептидами
NZ580866A (en) *	2007-04-10	2011-02-25	Myriad Pharmaceuticals Inc	Method of treating brain cancer
NZ580868A (en) *	2007-04-10	2011-07-29	Myriad Pharmaceuticals Inc	Dosages and methods for the treatment of cancer
WO2008124823A1 (en) *	2007-04-10	2008-10-16	Myriad Genetics, Inc.	Method of treating melanoma
WO2008124828A1 (en) *	2007-04-10	2008-10-16	Myriad Genetics, Inc.	Methods for treating vascular disruption disorders
AU2008236997A1 (en) *	2007-04-10	2008-10-16	Myrexis, Inc.	Methods for treating cancer
CN103501823B (zh)	2011-02-17	2018-05-04	杜兰教育基金委员会	多组分组合物以及它们的用途
CN105283201B (zh) *	2013-03-14	2019-08-02	斯克利普斯研究所	靶向剂抗体偶联物及其用途
AU2017213886B2 (en)	2016-02-04	2024-03-07	The California Institute For Biomedical Research	Humanized anti-CD3 antibodies, conjugates and uses thereof
JP6989529B2 (ja)	2016-02-09	2022-01-05	シーディーアールディーベンチャーズインコーポレイテッド	ソマトスタチン受容体アンタゴニスト化合物及びその使用方法
WO2017165607A1 (en)	2016-03-24	2017-09-28	The Administrators Of The Tulane Educational Fund	Conjugates of tacrolimus, their compositions, and their uses
US12485191B2 (en) *	2017-11-28	2025-12-02	Board Of Regents Of The Univeristy Of Nebraska	Radiopharmaceuticals and methods of use thereof
KR20200121816A (ko)	2018-02-02	2020-10-26	리플 테라퓨틱스 코포레이션	스테로이드 이량체를 포함하는 유리 제제 및 이의 용도
AU2019234523B2 (en) *	2018-03-15	2024-09-12	Osaka University	Pharmaceutical composition containing 211At-labeled amino acid derivative, and method for producing said pharmaceutical composition
WO2020154815A1 (en)	2019-02-01	2020-08-06	Ripple Therapeutics Corporation	Crystalline forms of dexamethasone dimers and uses thereof
US20220347305A1 (en)	2019-08-07	2022-11-03	Ripple Therapeutics Corporation	Controlled release drug dimers
CA3176134A1 (en)	2020-05-01	2021-11-04	Ripple Therapeutics Corporation	Heterodimer compositions and methods for the treatment of ocular disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4904642A (en)	1985-09-12	1990-02-27	The Administrators Of The Tulane Educational Fund	Therapeutic somatostatin analogs
US4812590A (en)	1987-06-25	1989-03-14	Merck & Co., Inc.	Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US5073541A (en)	1987-11-18	1991-12-17	Administrators Of The Tulane Educational Fund	Treatment of small cell lung cancer with somatostatin analogs
US5753627A (en)	1988-12-05	1998-05-19	Novartis Ag	Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5633263A (en)	1989-04-26	1997-05-27	The Administrators Of The Tulane Educational Fund	Linear somatostatin analogs
DE69018226T2 (de)	1989-07-20	1995-09-21	Sandoz-Patent-Gmbh, 79539 Loerrach	Markierte polypeptidderivate.
ES2075244T3 (es) *	1990-04-06	1995-10-01	Univ Tulane	Analogos de la somatostatina.
US5443815A (en)	1991-11-27	1995-08-22	Diatech, Inc.	Technetium-99m labeled peptides for imaging
US5411943A (en)	1992-02-25	1995-05-02	Biomeasure, Inc.	Hepatoma treatment with somatostatin analogs
US5620675A (en)	1992-06-23	1997-04-15	Diatech, Inc.	Radioactive peptides
US5597894A (en)	1995-06-05	1997-01-28	The Louisiana State University Medical Center Foundation	Multi-tyrosinated somatostatin analogs
US6051554A (en) *	1995-06-07	2000-04-18	Peptor Limited	Conformationally constrained backbone cyclized somatostatin analogs
US5770687A (en)	1995-06-07	1998-06-23	Peptor Limited	Comformationally constrained backbone cyclized somatostatin analogs
US5708135A (en)	1995-09-29	1998-01-13	Biomeasure Incorporated	Cyclic peptide analogs of somatostatin
US5750499A (en)	1995-10-18	1998-05-12	The Salk Institute For Biological Studies	Receptor-selective somatostatin analogs
US5843903A (en)	1995-11-27	1998-12-01	The Administrators Of The Tulane Educational Fund	Targeted cytotoxic anthracycline analogs
US6156725A (en)	1996-08-16	2000-12-05	National Institute Of Immunology	Drug for the treatment of cancer
WO1998047524A1 (en)	1997-04-22	1998-10-29	Curators Of The University Of Missouri	Gastrin receptor-avid peptide conjugates
AU4267700A (en)	2000-01-13	2001-07-19	Academia Sinica	Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
JP3996897B2 (ja) *	2001-06-08	2007-10-24	ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス	ソマトスタチン−ドーパミンキメラ類似体

2002
- 2002-09-20 JP JP2003531872A patent/JP4799820B2/ja not_active Expired - Fee Related
- 2002-09-20 KR KR10-2004-7004173A patent/KR20040047846A/ko not_active Ceased
- 2002-09-20 BR BR0212897-7A patent/BR0212897A/pt not_active IP Right Cessation
- 2002-09-20 WO PCT/US2002/030143 patent/WO2003028527A2/en not_active Ceased
- 2002-09-20 NZ NZ532204A patent/NZ532204A/en not_active IP Right Cessation
- 2002-09-20 CN CNA028230817A patent/CN1589151A/zh active Pending
- 2002-09-20 US US10/490,326 patent/US7326685B2/en not_active Expired - Fee Related
- 2002-09-20 AU AU2002341792A patent/AU2002341792B2/en not_active Ceased
- 2002-09-20 EP EP02775944A patent/EP1435826A4/en not_active Withdrawn
- 2002-09-20 PL PL02369336A patent/PL369336A1/xx not_active Application Discontinuation
- 2002-09-20 IL IL16099302A patent/IL160993A0/xx unknown
- 2002-09-20 MX MXPA04002621A patent/MXPA04002621A/es active IP Right Grant
- 2002-09-20 CA CA002461099A patent/CA2461099A1/en not_active Abandoned
2004
- 2004-03-19 IS IS7189A patent/IS7189A/is unknown
- 2004-03-21 IL IL160993A patent/IL160993A/en not_active IP Right Cessation
- 2004-03-22 NO NO20041186A patent/NO20041186L/no not_active Application Discontinuation
- 2004-04-06 ZA ZA200402698A patent/ZA200402698B/en unknown

Also Published As

Publication number	Publication date
CN1589151A (zh)	2005-03-02
EP1435826A4 (en)	2009-07-15
NO20041186L (no)	2004-05-05
US20050070470A1 (en)	2005-03-31
BR0212897A (pt)	2004-08-24
EP1435826A2 (en)	2004-07-14
WO2003028527A3 (en)	2003-10-30
NZ532204A (en)	2006-04-28
WO2003028527A2 (en)	2003-04-10
MXPA04002621A (es)	2004-07-08
WO2003028527A8 (en)	2004-04-15
CA2461099A1 (en)	2003-04-10
KR20040047846A (ko)	2004-06-05
PL369336A1 (en)	2005-04-18
IL160993A0 (en)	2004-08-31
JP2005505580A (ja)	2005-02-24
JP4799820B2 (ja)	2011-10-26
AU2002341792B2 (en)	2007-09-06
IL160993A (en)	2011-04-28
US7326685B2 (en)	2008-02-05
ZA200402698B (en)	2005-04-25

Publication	Publication Date	Title
IS7189A (is)	2004-03-19	Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra
DK1404809T3 (da)	2014-03-17	Forbedrede hudsubstitutter og anvendelser deraf
DE60237823D1 (de)	2010-11-11	Medizinisches behandlungsinstrument
NO20030832D0 (no)	2003-02-21	Kondenserte cykliske forbindelser og medisinsk anvendelse derav
DK1417175T3 (da)	2013-10-28	Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
NO20044195L (no)	2004-10-01	Biofosfoninsyrer for behandling og prevensjon av osteoprose
NO20035156D0 (no)	2003-11-20	Fremgangsmåter for brönnbehandling
NO20034159D0 (no)	2003-09-18	Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
FR2846545B1 (fr)	2005-09-09	Implant d'osteosynthese intramedullaire
NO20051503D0 (no)	2005-03-21	Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
IL157328A0 (en)	2004-02-19	Treatment involving dkk-1 or antagonists thereof
GB0201674D0 (en)	2002-03-13	Medical treatment
DE60205718D1 (de)	2005-09-29	Flexibler wellschlauch und anschlussverfahren
DE60223576D1 (de)	2007-12-27	Hautbehandlungszusammensetzung
GB0218879D0 (en)	2002-09-25	Medical treatment
DE60227963D1 (de)	2008-09-11	Behandlungssystem
DK1355668T3 (da)	2008-05-05	Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
IS7275A (is)	2004-05-21	Samsetning fyrir hollegg og notkun á henni
DE60220220D1 (de)	2007-07-05	Blutbehandlungssystem
DE60222664D1 (de)	2007-11-08	Hautbehandlungsmittel
SG106109A1 (en)	2004-09-30	Tomography or curved surfaces
DE60114244D1 (de)	2005-11-24	Osteosynthesevorrichtung
DE60228736D1 (de)	2008-10-16	Menschliches bmcc1-gen
AU2003298547A8 (en)	2004-05-04	2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety
GB0303016D0 (en)	2003-03-12	Science technology and invention processor version 1.0.